Advanced Search

Study Preview



Study Title and Description

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.



Key Questions Addressed
7 Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?
  • Comments Comments (
    0
    ) |
8 Key Question 8. What are the harms of currently recommended antiviral treatments?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Author Hézode C., Asselah T., Reddy KR., Hassanein T., Berenguer M., Fleischer-Stepniewska K., Marcellin P., Hall C., Schnell G., Pilot-Matias T., Mobashery N., Redman R., Vilchez RA., Pol S.
Country Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Inserm, Créteil, France. Electronic address: christophe.hezode@hmn.aphp.fr.
Year 2015
Numbers Pubmed ID: 25837829

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.